Sector: Cardiovascular medical devices
Platform: StartEngine
Stage: Early
Minimum investment: ~$499
What They Do
Heart failure solutions is developing the PeriCut System, a minimally invasive therapy for heart failure with preserved ejection fraction (HFpEF).
Why It Might Be the Next Big Thing
HFpEF accounts for roughly half of all heart failure cases, yet treatment options remain limited. A device that improves diastolic function with a minimally invasive approach could address a major therapeutic gap.
Who’s Backing Them
A mix of early investors and retail participants on StartEngine.
Snapshot
In an FDA-approved Early Feasibility Study
Lean team focused on clinical development
Pre-commercial with significant runway
Progress driven by clinical milestones
My Take
A high-stakes opportunity centered on clinical outcomes. The indication is large, and success depends entirely on trial data.